Incyte Corporation (INCY) News

Incyte annonce l'approbation de la FDA pour le Zynyz® (rétifanlimab-dlwr), qui devient ainsi le premier et seul traitement de première intention pour les patients atteints de cancer anal de stade avancé aux États-Unis

Zynyz® (rétifanlimab-dlwr), un inhibiteur de PD-1, est maintenant approuvé pour le traitement du carcinome...

Incyte verkündet FDA-Zulassung von Zynyz® (Retifanlimab-dlwr), die erste und einzige zugelassene Erstlinienbehandlung in den USA für Patienten mit fortgeschrittenem Analkrebs

Zynyz® (Retifanlimab-dlwr), ein PD-1-Inhibitor, ist jetzt für die Behandlung von fortgeschrittenem...

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Zynyz® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell...

Form 8-K - Current report

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,413 shares of the...

Incyte to Present at Upcoming Investor Conference

Incyte (Nasdaq:INCY) announced today that it will present at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 1:40 pm...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs

– Total revenues of $1,053 million in the first quarter (Q1'25) (+20% Y/Y); total product revenues of $922 million in Q1'25 (+26%Y/Y) – Jakafi®...

Incyte présentera de nouvelles données sur ses traitements oncologiques en phase précoce lors du congrès annuel 2025 de l’American Association for Cancer Research

Incyte (Nasdaq : INCY) a annoncé aujourd’hui qu’elle présentera de nouvelles données préliminaires issues de son portefeuille de traitements...

Incyte präsentiert Daten aus frühen Phasen der Onkologieforschung auf der Jahrestagung 2025 der American Association for Cancer Research

Incyte (Nasdaq:INCY) gab heute bekannt, dass das Unternehmen auf der Jahrestagung 2025 der American Association for Cancer Research (AACR) vom...

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025

Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association...